News

Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Zacks Investment Research on MSN22h
Here's Why Moderna (MRNA) Fell More Than Broader Market
Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...
Novartis2d
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Mobileye Global, Inc. Class A (MBLY) Gets a Buy from Evercore ISI
Detailed price information for Mobileye Global Inc Cl A (MBLY-Q) from The Globe and Mail including charting and trades.
INTC, PARA, MRNA and more – J.P. Morgan’s best short ideas for the second half of 2025
J.P. Morgan’s U.S. equity research analysts compiled their list of “most compelling structural and tactical short ideas” for ...
Barclays Sticks to Their Hold Rating for Mobileye Global, Inc. Class A (MBLY)
Detailed price information for Mobileye Global Inc Cl A (MBLY-Q) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN1d
Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings
Healthcare plan provider, Molina Healthcare, Inc. MOH, is set to report second-quarter 2025 results on July 23, 2025, after ...
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine.
International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum ...